FUKUSHIMA JOURNAL OF MEDICAL SCIENCE
Online ISSN : 2185-4610
Print ISSN : 0016-2590
ISSN-L : 0016-2590
Clinical factors associated with arteriovenous fistula patency among Japanese patients undergoing hemodialysis: a single-center retrospective study
Hiroki EjiriKenichi TanakaHiroshi KimuraYukiko KouchiNaoto YoshidaHiroaki ShimmuraHiroshi KawaguchiAkihiko OzakiMasaharu TsubokuraJunichiro James Kazama
Author information
JOURNAL OPEN ACCESS FULL-TEXT HTML Advance online publication

Article ID: 26-00015

Details
Abstract

Introduction:Adequate vascular access is essential for stable hemodialysis treatment. Several clinical factors have been reported to affect arteriovenous fistula (AVF) patency;however, data focusing on Japanese patients remain limited. This study aimed to evaluate one-year AVF patency rates and associated clinical factors in Japanese patients.

Methods:We retrospectively analyzed 580 patients who underwent AVF creation at a single center between July 2013 and December 2020. One-year AVF patency rates were estimated using the Kaplan-Meier method, and factors associated with AVF failure were examined using Cox proportional hazards regression.

Results:The overall one-year primary, assisted primary, and secondary AVF patency rates were 15.4%, 78.3%, and 79.1%, respectively. In multivariate analyses, older age (adjusted HR 1.02, 95% CI 1.00-1.04), reduced preoperative cardiac function (ejection fraction ≤50%;adjusted HR 1.98, 95% CI 1.20-3.26), and catheter use at dialysis initiation (adjusted HR 1.51, 95% CI 1.02-2.22) were associated with an increased risk of AVF failure.

Conclusions:In Japanese patients undergoing hemodialysis, older age, reduced cardiac function, and catheter use at dialysis initiation were factors associated with one-year AVF failure. These findings highlight the importance of minimizing catheter use and assessing cardiovascular status when planning vascular access.

Content from these authors
© 2026 The Fukushima Society of Medical Science

This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license.
https://creativecommons.org/licenses/by-nc-sa/4.0/
Previous article Next article
feedback
Top